Neuroprotective potential of gliflozins

Gliflozins are a relatively new class of oral antihyperglycemic drugs that are increasingly being introduced into routine practice in the treatment of patients with type 2 diabetes mellitus (DM2). The hypoglycemic effect of gliflozins is associated with the stimulation of glucosuria, however, in add...

Full description

Saved in:
Bibliographic Details
Main Authors: A. S. Kokin, L. A. Suplotova
Format: Article
Language:English
Published: Endocrinology Research Centre 2023-12-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/13085
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849729886786158592
author A. S. Kokin
L. A. Suplotova
author_facet A. S. Kokin
L. A. Suplotova
author_sort A. S. Kokin
collection DOAJ
description Gliflozins are a relatively new class of oral antihyperglycemic drugs that are increasingly being introduced into routine practice in the treatment of patients with type 2 diabetes mellitus (DM2). The hypoglycemic effect of gliflozins is associated with the stimulation of glucosuria, however, in addition to a pronounced hypoglycemic effect and high safety, these drugs also have many pleiotropic properties, due to the presence of many direct and indirect points of application. The purpose of this paper is to provide an overview of the currently best studied neuroprotective effects of this class of drugs. As materials in the course of the work, studies of foreign colleagues published in the period 2008–2022 were used. Analysis of the works showed that the neuroprotective effect of gliflozins is associated with many different mechanisms. Thus, gliflozins realize an anti-inflammatory effect by activating the M2 subpopulation of macrophages, reducing pro-inflammatory neurotransmitters (related primarily to the inflammasome). In addition, by reducing the activity of the mTOR signaling pathway, the drugs reduce the amount of beta-amyloid and improve neurotransmission. A group of works also showed the antiacetylcholinesterase effect of gliflozins, not to mention the decrease in the intensity of non-enzymatic protein glycation and insulin resistance. All of the above mechanisms provide an anti-inflammatory, anti-atherogenic effect, improve cognitive abilities in patients, reduce the frequency of hemorrhagic stroke, and can also potentially improve prognosis in patients with Alzheimer’s disease (AD). The effects described above were obtained during preclinical trials and many experimental studies, and some effects have already demonstrated their consistency in prospective clinical trials. However, the data obtained are still insufficient to form clear indications for this class of drugs in neurology, so the topic requires further study and clinical trials.
format Article
id doaj-art-bf4cd684a9c042a885486be2632413e6
institution DOAJ
issn 2072-0351
2072-0378
language English
publishDate 2023-12-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj-art-bf4cd684a9c042a885486be2632413e62025-08-20T03:09:03ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782023-12-0126659660210.14341/DM1308511060Neuroprotective potential of gliflozinsA. S. Kokin0L. A. Suplotova1Tyumen State Medical UniversityTyumen State Medical UniversityGliflozins are a relatively new class of oral antihyperglycemic drugs that are increasingly being introduced into routine practice in the treatment of patients with type 2 diabetes mellitus (DM2). The hypoglycemic effect of gliflozins is associated with the stimulation of glucosuria, however, in addition to a pronounced hypoglycemic effect and high safety, these drugs also have many pleiotropic properties, due to the presence of many direct and indirect points of application. The purpose of this paper is to provide an overview of the currently best studied neuroprotective effects of this class of drugs. As materials in the course of the work, studies of foreign colleagues published in the period 2008–2022 were used. Analysis of the works showed that the neuroprotective effect of gliflozins is associated with many different mechanisms. Thus, gliflozins realize an anti-inflammatory effect by activating the M2 subpopulation of macrophages, reducing pro-inflammatory neurotransmitters (related primarily to the inflammasome). In addition, by reducing the activity of the mTOR signaling pathway, the drugs reduce the amount of beta-amyloid and improve neurotransmission. A group of works also showed the antiacetylcholinesterase effect of gliflozins, not to mention the decrease in the intensity of non-enzymatic protein glycation and insulin resistance. All of the above mechanisms provide an anti-inflammatory, anti-atherogenic effect, improve cognitive abilities in patients, reduce the frequency of hemorrhagic stroke, and can also potentially improve prognosis in patients with Alzheimer’s disease (AD). The effects described above were obtained during preclinical trials and many experimental studies, and some effects have already demonstrated their consistency in prospective clinical trials. However, the data obtained are still insufficient to form clear indications for this class of drugs in neurology, so the topic requires further study and clinical trials.https://www.dia-endojournals.ru/jour/article/view/13085neuroprotectionalzheimer’s diseasegliflozinssodium-glucose cotransporter-2 inhibitorsdiabetes mellitushemorrhagic strokecognitive impairment
spellingShingle A. S. Kokin
L. A. Suplotova
Neuroprotective potential of gliflozins
Сахарный диабет
neuroprotection
alzheimer’s disease
gliflozins
sodium-glucose cotransporter-2 inhibitors
diabetes mellitus
hemorrhagic stroke
cognitive impairment
title Neuroprotective potential of gliflozins
title_full Neuroprotective potential of gliflozins
title_fullStr Neuroprotective potential of gliflozins
title_full_unstemmed Neuroprotective potential of gliflozins
title_short Neuroprotective potential of gliflozins
title_sort neuroprotective potential of gliflozins
topic neuroprotection
alzheimer’s disease
gliflozins
sodium-glucose cotransporter-2 inhibitors
diabetes mellitus
hemorrhagic stroke
cognitive impairment
url https://www.dia-endojournals.ru/jour/article/view/13085
work_keys_str_mv AT askokin neuroprotectivepotentialofgliflozins
AT lasuplotova neuroprotectivepotentialofgliflozins